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Abstract The preoperative nutritional and immunological
statuses have an important impact in predicting the survival
outcome of patients with various types of malignant tumors.
Our study aimed to explore the clinical significance and pre-
dictive prognostic potential of Onodera’s prognostic nutrition-
al index (PNI) in patients with colorectal carcinoma. This
retrospective study included a total of 1321 patients who were
diagnosed with colorectal cancer and who had been surgically
treated between January 1994 and December 2007. The PNI
level was determined according the following formula: 10×
serum albumin (g/dL)+0.005×total lymphocyte count (per
mm3). The impact of PNI on clinicopathological features
and overall survival (OS) was determined. The optimal cutoff
value of PNIwas set at 45. Patients in the low-PNI group had a
greater potential to have aggressive histological features, ad-
vanced tumors (T), nodal involvement (N), metastasis (M),
and TNM stage than those in the high-PNI group. The low-
PNI group had a worse OS than the high-PNI group (5-year
survival rate 56.1 vs 64.8 %, respectively; P<0.05).
Furthermore, the PNI value was an independent prognostic
factor for colorectal cancer in this study. The OS was signifi-
cantly lower in the low-PNI group than in the high-PNI group
in patients with TNM stage II and III diseases. Preoperative
PNI i s a s imp l e and use fu l marke r t o p r ed i c t
clinicopathological features and long-term survival outcome
in patients with colorectal carcinoma. PNI analysis should be
included in the routine assessment of patients with locally
advanced colorectal cancer.
Keywords Prognostic nutritional index . Clinicopathological
feature . Survival . Colorectal cancer
Introduction
According to GLOBOCAN 2012 database, there were 253,
000 new cases of colorectal cancer and 139,000 cases of death
due to colorectal cancer; these accounted for 18.6 and 20.0 %
of cancers and cancer deaths worldwide, respectively.
Moreover, the incidence of new cases of colorectal cancer in
China has increased in recent years [1–4]. Surgical resection is
the most important method of treatment for colorectal cancer.
Hence, it is important to determine preoperative predictive
prognostic markers for patients with colorectal cancer who
undergo surgical treatment.
The immunological and nutritional statuses have both been
deemed as useful preoperative indexes to assess surgical risk,
postoperative morbidity, and mortality [5]. An increasing
number of studies have shown that immunonutritional status
can also be a powerful means of predicting survival outcome
[6, 7]. Onodera’s prognostic nutritional index (PNI) is consid-
ered a simple and useful index to reflect the preoperative nu-
tritional and immunological condition, and it can be easily
calculated using the serum albumin level and peripheral blood
total lymphocyte counts. The PNI was originally used to eval-
uate the risk of postoperative complications and mortality [8]
in gastrointestinal tract surgery, and it has become a powerful
prognostic parameter for various types of cancer, such as co-
lorectal cancer [9], gastric cancer [10], pancreatic cancer [11],
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and hepatocellular carcinoma [12]. However, few studies have
evaluated the clinical importance of PNI in patients with co-
lorectal cancer in China, and most of the related studies have
had a small sample size. Hence, we performed a retrospective
analysis to study the clinical importance and prognostic effect




Between January 1994 and December 2007, a total of 1732
patients diagnosed with primary colorectal cancer underwent
surgical treatment in the gastrointestinal-pancreatic surgery
department of the First Affiliated Hospital of Sun Yat-sen
University. Thirty-eight patients with multiple cancer, 249
with incomplete follow-up data, 57 with recurrent colorectal
cancer, 155 with incomplete serum albumin data, and 57 with
incomplete peripheral blood lymphocyte count data were ex-
cluded from this study. At last, 1321 patients were included in
this study. Informed consent was obtained from all individual
participants included in the study, and this study was approved
by the Ethics Committees of the First Affiliated Hospital of
Sun Yat-sen University.
PNI and data
The preoperative peripheral blood samples were collected to
obtain the serum albumin and total lymphocyte count. The
Onodera’s PNI value was calculated using the following for-
mula: 10×serum albumin (g/dL)+0.005×total lymphocyte
count (per mm3).
The clinicopathological factors including demographics
(age and sex), perioperative blood transfusion, clinical
features (tumor size, location, and gross type), histologi-
cal type, surgical approach, and cancer stage were collect-
ed using a larger clinical database of the gastrointestinal-
pancreatic surgery department of the First Affiliated
Hospital of Sun Yat-sen University since January 1994.
Tumor size was determined according to the largest diam-
eter, and patients were divided into two groups based on
the median tumor diameter (>5 and <5 cm). We deemed
well-differentiated and moderately differentiated adeno-
carcinoma to be the well-differentiated histological type,
and poorly differentiated, undifferentiated, mucinous, and
signet ring cell adenocarcinoma to be the poorly differen-
tiated histological type. Tumor stage was classified ac-
cording to the seventh edition of the American Joint
Committee on Cancer (AJCC) TNM classification system.
Follow-up
The patients received follow-up until December 2014. The
patients were followed up every 3 months during the first
two postoperative years, every 6 months for the next 3 years,
and annually thereafter. Physical examination, chest radiogra-
phy, colonoscopy, peripheral blood tumor marker measure-
ments (CEA, CA199, CA125, and AFP), and abdominal com-
puted tomography or ultrasonography were performed during
the follow-up period. The follow-up rate of this study was
87.7 %.
Statistical analysis
The statistical analysis was performed using SPSS analysis
software program (SPSS 18.0, IBM, Chicago, IL, USA). A
receiver operating characteristics (ROC) curve was generated
to determine the sensitivity and specificity of the PNI value for
predicting 5-year overall survival (OS), and the Youden index
was determined to calculate the optimal cutoff value of PNI.
The categorical variables are presented as numbers and per-
centages, and they were compared using the chi-squared or
Fisher’s tests. Survival comparison and survival curves were
performed and generated using the Kaplan-Meier method, and
the 5-, 10-, and 15-year OS rates were calculated using the
life-table method. Multivariate and univariate analysis data
were obtained from the Cox proportional hazard model. A P
value less than 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 1321 patients with colorectal cancer were analyzed
in this study. The baseline clinical and pathological character-
istics of all included patients are shown in Table 1. Themedian
age of patients was 57.5 years (range, 18–91 years). There
were 777 (58.8 %) men and 544 (41.2 %) women; 609
(46.1 %) patients had colon cancer and 712 (53.9 %) patients
had rectal cancer.
ROC curve analysis
The mean value of PNI was 50.2 (range, 24.9–70.0).
According to 5-year survival rate, the area under the ROC
curve for the PIN was 0.625 (P<0.001). When the PNI value
was 45, the Youden index was maximal and the sensitivity and
specificity for 5-year OS were 0.849 and 0.690, respectively
(Fig. 1). Hence, we divided the patients into two groups based
on the previously described optimal cutoff value of PNI: the
high-PNI group (PNI≥45, n=772) and the low-PNI group
(PNI<45, n=549).
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Table 1 The correlation between PNI status and various of clinicopathological factors
Variable Low-PNI group High-PNI group χ2 value P value
Age (years) 10.936a 0.001
≤60 253 (46.1 %) 427 (55.3 %)
>60 296 (53.9 %) 345 (44.7 %)
Gender 0.646a 0.422
Male 330 (60.1 %) 447 (57.9 %)
Female 219 (39.9 %) 325 (42.1 %)
Blood transfusion 4.432a 0.035
No 412 (75.0 %) 617 (79.9 %)
Yes 137 (25.0 %) 155 (20.1 %)
Tumor location 0.272 0.602
Colon 290 (52.8 %) 419 (54.3 %)
Rectum 259 (47.2 %) 353 (45.7 %)
Tumor gross types 20.139a <0.001
Mass 226 (41.2 %) 276 (35.8 %)
Ulcerated 215 (39.2 %) 393 (50.9 %)
Infiltrative 108 (19.7 %) 103 (13.3 %)
Histology 5.559a 0.018
Well differentiated 429 (78.1 %) 643 (83.3 %)
Poor differentiated 120 (21.9 %) 129 (16.7 %)
Tumor size(cm) 26.017a <0.001
≤5 320 (58.3 %) 554 (71.8 %)
>5 229 (41.7 %) 218 (28.2 %)
T stage 33.910a 0.001
T1 20 (3.6 %) 41 (5.3 %)
T2 77 (14.0 %) 170 (22.0 %)
T3 289 (52.6 %) 425 (55.1 %)
T4 163 (29.7 %) 136 (17.6 %)
N stage 7.066a 0.029
N0 176 (32.1 %) 302 (39.1 %)
N1 173 (31.5 %) 224 (29.0 %)
N2 200 (36.4 %) 246 (31.9 %)
M stage 9.796a 0.002
M0 420 (76.5 %) 644 (83.4 %)
M1 129 (23.5 %) 128 (16.6 %)
TNM stage 18.736a 0.001
I 52 (9.5 %) 125 (16.2 %)
II 205 (37.3 %) 286 (37.0 %)
III 163 (29.7 %) 233 (30.2 %)
IV 129 (23.5 %) 128 (16.6 %)
Dukes stage 13.762a 0.003
A 46 (8.4 %) 95 (12.3 %)
B 130 (23.7 %) 207 (26.8 %)
C 244 (44.4 %) 342 (44.3 %)
D 129 (23.5 %) 128 (16.6 %)
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Association between PNI and clinicopathological features
The association between PNI status and various clinicopatho-
logical factors is shown in Table 1. Among all 1321 patients,
there were no significant distribution differences in sex and
tumor location between the two groups. Older age (age
≥60 years), larger tumor size, worse gross type, and poorly
differentiated histological type were more frequently observed
in the low-PNI group. Additionally, patients in the low-PNI
group had a higher incidence of perioperative blood transfu-
sion. Moreover, patients in the low-PNI group were more
likely to have advanced tumors (T), nodal involvement (N),
metastasis (M), TNM stage, and Dukes stage.
Association between PNI and survival
During the follow-up period, the median survival time of all
patients was 86.3 months and the average survival time was
88.6 months (range, 1.0–235.0 months). At the last follow-up,
766 (58.0 %) patients had died. The 5-, 10-, and 15-year OS
rates were 61.2, 45.6, and 35.9, respectively.
The relationship between PNI and OS is presented in
Fig. 2. A low PNI value was associated with reduced OS
(P<0.05). The 5-, 10-, and 15-year OS rates were 56.1,
40.3, and 31.5 % in the low-PNI group and 64.8, 49.4, and
38.9 % in the high-PNI group, respectively.
To further investigate the consistency of PNI in different
TNM stages, we found no survival differences among patients
with TNM I and IV stages between the two groups (P=0.535
and 0.454, respectively, shown in Fig. 3a, d). Furthermore,
patients in the high-PNI group had a better OS than those in
the low-PNI group with TNM II and III stages (P=0.042 and
0.049, respectively, shown in Fig. 3b, c).
Prognostic significance of PNI for overall survival
Results of univariate analysis for OS are shown in Table 2,
which shows the factors associated with a statistically worse
OS, such as age ≥60 years, perioperative blood transfusion,
larger tumor size ≥5 cm, infiltrative gross type, poor histolog-
ical type, advanced Tstage [T4 vs (T3+T2+T1)], lymph node
involvement, distant metastasis, advanced TNM stage [(III+
IV) vs (I+II)], advanced Dukes stage [(C+D) vs (A+B)],
palliative surgery, and low PNI value; sex and tumor location
were not associated with survival. Multivariate analysis re-
vealed that only the low PNI value (hazard ratio, 0.862;
95 % confidence interval, 0.527–0.932; P=0.014), infiltrative
gross type, advanced T stage, lymph node involvement, and
distant metastasis were independent prognostic factors for ad-
verse OS of colorectal cancer patients in this study.
Discussion
The PNI, a simple and useful systemic inflammation-based
prognostic score, is calculated based on laboratory assess-
ments of total lymphocyte count and serum albumin level
[8] and can reflect the pretreated host immunological and nu-
tritional status. Low PNI was first found to be a predictor of a
high risk of short-term postoperative complications in the gas-
trointestinal tract. Recently, increasing evidence revealed that
low PNI was also related to reduced survival in various types
of malignant tumors [10–12]. In this retrospective study, we
Fig. 1 Receiver operating characteristic (ROC) curve analysis for the
prognostic nutritional index. When the PNI value was 45, the Youden
index was maximal (0.169) and the sensitivity and specificity for 5-year
OS were 0.849 and 0.690, respectively
Fig. 2 Kaplan-Meier analysis of overall survival (OS) for a total of 1321
cases with colorectal cancer according to the prognostic nutritional index
(PNI) value. The low-PNI group had a worse OS rate than the high-PNI
group (P<0.05)
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Fig. 3 Kaplan-Meier analyses of overall survival (OS) for a total of 1321
patients with colorectal cancer according to the prognostic nutritional
index (PNI) value among patients with stage I (a, P=0.535), stage II (b,
P=0.042), stage III (c, P=0.049), and stage IV (d, P=0.454) disease.
Patients with stage II and III disease in the high-PNI group had a better
survival outcome than those in the low-PNI group
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demonstrated that low PNI was associated with older ages and
aggressive clinicopathological features, which led to a worse
overall survival for patients with colorectal cancer. Hence,
from the multivariate analysis, PNI was a worse independent
prognostic factor in our study.
It was widely accepted that the host-related inflamma-
tory response plays an important role in tumorigenesis,
tumor progression, and metastasis through recruitment of
regulatory T lymphocytes and cytokines, including
interleukin-1 (IL-1), IL-6, and tumor necrosis factor α
[13]. Moreover, in patients with malignant tumors, the
presence of inflammation can be reflected by various
preoperative hematological inflammation-based prognos-
tic scores [14], such as the neutrophil-to-lymphocyte ra-
tio, platelet-to-lymphocyte ratio, Glasgow Prognostic
Score, and PNI. However, few studies have investigated
the clinical impact of PNI on the clinicopathological fea-
tures and survival outcome of patients with colorectal
cancer.
In previous reports, various cutoff values have been used
for PNI. Some Japanese authors set the PNI cutoff value at 40
for patients with colorectal cancer [15–17]. Ikeya found the
optimal cutoff value for PNI was 44.5 according to the ROC
curve analysis [18]. However, for other kinds of malignant
tumors, most studies usually set the cutoff value of PNI at
45, because PNI<45 was regarded as malnutrition and was
accompanied by a high risk of postoperative complications. In
our large cohort study, with the help of the ROC curve anal-
ysis for the 5-year overall survival of colorectal cancer pa-
tients, we found that the optimal cutoff point for PNI was
45, similar to the result of Mohri’s study [9].
Nozoe et al. retrospectively analyzed 219 patients with co-
lorectal cancer [15]. Their study revealed no association be-
tween PNI and lymph node involvement, and a close relation-
ship between PNI and TNM stage that may be reflected by the
tumor depth. Our study also demonstrated the significant val-
ue of PNI in predicting the aggressive clinicopathological fea-
tures of patients with colorectal cancer, including advanced
tumor depth, lymph node involvement, distant metastasis,
and TNM classification.
The initial aim of the Onodera PNI was to evaluate the
nutritional and immunological status to predict the short-
term postoperative outcome of patients with gastrointestinal
malignancy. Increasing evidence reported that PNI had a prog-
nostic impact on the long-term survival outcome of patients in
with numerous malignant carcinomas. Hong found that the
low PNI group had a worse median OS time and that low
PNI was an independent significant prognostic factor for
worse OS [19]. Similarly, Ishizuka revealed that patients with
gastric cancer and higher PNI (>45) had a better postoperative
survival rate after total gastrectomy [20]. Our multivariate
Cox analysis clearly demonstrated that PNI was an indepen-
dent prognostic survival factor for patients with colorectal
cancer. Although some research has confirmed the clinical
impact of PNI in patients with unresectable metastatic colo-
rectal cancer, in our study, no survival difference was ob-
served in the OS rate with respect to the different pretreated
PNI levels for those with stage IV disease. Furthermore, we
found that the OS was significantly worse in the low-PNI
group only among those with stages II and III disease. A
similar result was found by Jiang et al. [21], who found that
when the cutoff value of PNI was set at 46, the 5-year survival
Table 2 Univariate and multivariate analyses for overall survival of 1321 cases with colorectal cancer
Factor Univariate analyses Multivariate analyses
χ2 value HR P value χ2 value HR P value
Age (>60 years) 21.889 1.405 0.001
Gender (male) 0.023 0.878
Blood transfusion (yes) 25.859 1.453 0.001
Tumor location (colon) 2.441 0.118
Size (>5 cm) 4.236 1.169 0.04
Gross type (ulcerated) 24.112 1.279 0.001 11.069 1.191 0.001
Histological type (poor differentiated) 23.434 1.521 0.001
T stage (T3+T4) 62.262 1.472 0.001 7.111 1.147 0.008
N stage (N1~3) 93.467 1.393 0.001 6.494 1.107 0.011
M stage (M1) 224.747 3.374 0.001 43.942 2.032 0.001
TNM stage (III+IV stage) 198.582 1.789 0.001
Dukes stage (C+D stage) 238.757 1.903 0.001
Surgical approach (radical) 241.337 5.463 0.001 102.463 3.367 0.001
PNI (<45) 14.258 0.759 0.001 3.953 0.862 0.047
HR hazard ratio
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rates were significantly lower in the low-PNI group among
patients with stage II and III disease. These results suggested
that low PNI might be associated with a worse prognosis in
patients with locally advanced cancer.
Some limitations to this study should be acknowledged.
First, this was a retrospective analysis, and some preoperative
hematological data were lost. Nevertheless, the large sample
size provided adequate statistical efficiency to explore the im-
pact of the PNI value on clinicopathological features and long-
termOS.Moreover, this study excluded patients who received
neoadjuvant chemotherapy or chemoradiotherapy, which may
have led to a negative impact on the survival outcome. Finally,
this was not a continuous study because there were a number
of cases with missing data due to incomplete serum albumin
or peripheral blood lymphocyte count data. Hence, further
research is needed to confirm these preliminary findings.
From this retrospective study, we can conclude that PNI is a
simple and effective marker for predicting the aggressive clin-
icopathological features and long-term survival outcome in
patients with colorectal cancer.
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